Cyclarity Therapeutics, a pioneering biotech company focused on reversing the root cause of cardiovascular disease (CVD), has announced its ongoing Series A Tranche 2 funding round. The company is seeking to raise between $2.6 million and $5.6 million to propel its clinical advancements, with over $1 million already committed.
Cyclarity is developing a revolutionary approach to treating CVD by targeting and eliminating toxic oxidized cholesterol molecules known as 7-ketocholesterol (7KC). Their lead drug candidate, UDP-003, is designed to rehabilitate foam cells and restore the body’s natural plaque-clearing process, addressing the underlying cause of atherosclerosis rather than merely managing its symptoms.
The Series A Tranche 2 funding will primarily support the Phase 1 clinical trial of UDP-003. This includes completing safety evaluations, advancing regulatory approvals, and preparing for Phase 2 clinical trials. The initial tranche of Series A raised approximately $6.4 million, enabling the company to achieve key preclinical and regulatory milestones, including an Innovation Passport award under the UK’s Innovative Licensing and Access Pathway (ILAP).
Dr. Matthew ‘Oki’ O’Connor, CEO of Cyclarity Therapeutics, emphasized the importance of this funding round: “With our clinical trial program well underway, this next tranche of funding is crucial in demonstrating the safety and efficacy of UDP-003 in human subjects. We are confident that our innovative approach will redefine the treatment landscape for cardiovascular disease.”
Cyclarity’s drug development efforts leverage cutting-edge AI-driven molecular design, enabling the rapid identification and optimization of cyclodextrins tailored for medical applications. This technological advantage positions the company at the forefront of the biotech industry, with potential applications extending beyond CVD.
Cyclodextrins are a family of cyclic oligosaccharides made up of glucose molecules linked together in a ring forming an inner cavity allowing them to form inclusion complexes with various molecules. Cyclarity’s UDP-300 is a cyclodextrin designed to take up 7KC (and has 300x more specificity for this oxidized cholesterol compared to non-oxidized cholesterol) which is then excreted in the patient’s urine.
The Series A Tranche 2 round presents an opportunity for investors to be part of a transformative shift in cardiovascular treatment. With a growing market exceeding $100 billion and limited disease-modifying therapies available, Cyclarity’s breakthrough approach offers significant commercial and therapeutic potential.
